BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - BioVie Inc. has announced a registered direct offering of 1,146,000 shares of its common stock at a price of $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds for working capital and general corporate purposes [1][2]. Group 1: Offering Details - The offering is priced at-the-market under Nasdaq rules, with total gross proceeds expected to be around $3.2 million before fees and expenses [1]. - The offering is set to close on or about October 29, 2024, pending customary closing conditions [2]. - ThinkEquity is acting as the sole placement agent for this offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes [2]. Group 3: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including neurological disorders and liver disease [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in Alzheimer's disease and Parkinson's disease [5]. - BioVie’s Orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].